Reaction

Adenocarcinoma reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,220 reports · 71 co-occurring drugs

As of the last recalculation, Adenocarcinoma appears in 2,220 FAERS reports alongside 71 co-occurring drug terms. The strongest observed disproportionality signal is ERLOTINIB (PRR 20.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Erlotinib	21	20.5	20.6
Pemetrexed	36	16.0	16.0
Erlotinib Hydrochloride	21	15.9	15.9
Panitumumab	26	15.7	15.8
Fluorouracil Cream, 0.5%	101	13.0	13.0
Fluorouracil	101	12.8	12.8
Pemetrexed Disodium	50	12.6	12.6
Gefitinib	12	12.5	12.5
Rabeprazole	27	11.6	11.6
Oxaliplatin	87	11.4	11.4
Granisetron Hydrochloride	12	10.8	10.8
Fulvestrant	37	10.7	10.7
Exemestane	24	10.6	10.6
Gemcitabine	38	9.2	9.2
Docetaxel Anhydrous	62	8.8	8.9
Docetaxel	62	8.8	8.9
Bendamustine Hcl	14	8.5	8.5
Capecitabine	78	8.2	8.3
Adalimumab-Adaz	45	8.1	8.1
Adalimumab-Fkjp	38	7.8	7.8
Adalimumab-Aaty	38	7.6	7.6
Rifampicin	8	7.4	7.4
Carboplatin	94	7.2	7.2
Gemcitabine Hydrochloride	40	7.2	7.2
Bendamustine Hydrochloride	9	7.1	7.1
Anastrozole Tablets	16	7.0	7.0
Letrozole	45	7.0	7.0
Fondaparinux Sodium	6	7.0	7.0
Bicalutamide	11	6.8	6.8
Imatinib Mesylate	20	6.8	6.8
Valsartan Oral	38	6.7	6.7
Alpelisib	6	6.5	6.5
Leucovorin Calcium	13	6.4	6.4
Paclitaxel (Aibumin-Bound)	53	6.2	6.2
Fosaprepitant Dimeglumine	9	6.2	6.2
Cisplatin	50	6.1	6.1
Bevacizumab	77	6.0	6.0
Paclitaxel	61	5.9	5.9
Irinotecan Hydrochloride	8	5.9	5.9
Infliximab	129	5.8	5.8
Obinutuzumab	10	5.7	5.7
Letrozole Tablets	29	5.7	5.7
Sirolimus	8	5.6	5.6
Granisetron	6	5.4	5.4
Trastuzumab	38	5.3	5.3
Crizotinib	7	5.2	5.2
Aflibercept	17	5.1	5.1
Atezolizumab	21	5.1	5.1
Aprepitant	10	5.1	5.1
Pazopanib Hydrochloride	14	4.9	4.9
Imatinib	9	4.8	4.8
Mepolizumab	25	4.8	4.8
Trifluridine And Tipiracil	5	4.4	4.4
Ipilimumab	20	4.4	4.4
Brinzolamide	4	4.3	4.3
Pembrolizumab	41	3.7	3.7
Durvalumab	8	3.7	3.7
Lapatinib	6	3.6	3.6
Trametinib	9	3.5	3.5
Vemurafenib	4	3.1	3.1
Acalabrutinib	4	3.1	3.1
Ustekinumab	33	3.1	3.1
Osimertinib	10	2.9	2.9
Abiraterone	4	2.8	2.8
Ranolazine	3	2.7	2.7
Enzalutamide	15	2.4	2.4
Olaparib	5	2.2	2.2
Velpatasvir And Sofosbuvir	3	2.2	2.2
Ranibizumab	6	2.1	2.1
Ranitidine Hydrochloride	10	1.7	1.7
Droxidopa	3	1.3	1.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.